Our Company

Management Team

A passion for innovation and collaboration.

Dicerna has assembled a driven management team with a broad and deep range of experience in the areas of science, clinical development and commercial operations. We are passionate about innovation. Our open, collaborative environment allows our people to freely exchange ideas, identify opportunities and advance programs based on sound, pragmatic decisions.

  • Douglas M. Fambrough III, Ph.D.

    President and Chief Executive Officer

    Douglas M. Fambrough, Ph.D., co-founded Dicerna in 2007 and has served as the Company’s chief executive officer since 2010. Prior to joining Dicerna as CEO, Doug specialized in financing innovative life science technology companies as a general partner with Oxford Bioscience Partners, a Boston-based venture capital firm.

    In 2003, Doug and two other investors founded Sirna Therapeutics, a first-generation RNA interference (RNAi) pioneer; he served on Sirna’s Board of Directors until the company was acquired by Merck for $1.1 billion in 2006. Other investments include Solexa, developer of the dominant ultra-high-throughput DNA sequencing platform, acquired by Illumina for $600 million; and Cambrios Technologies, which invented and now markets biologically inspired electronic materials for touch screens and flat panel displays. Before joining Oxford, Doug was a genomic scientist at the Whitehead/MIT Center for Genome Research (now known as the Broad Institute).

    Doug graduated from Cornell University and obtained his Ph.D. in genetics at the University of California, Berkeley.

  • Bob D. Brown, Ph.D.

    Chief Scientific Officer, Senior Vice President

    Bob Brown, Ph.D., joined Dicerna as senior vice president, research in 2008. Prior to joining Dicerna, he had a long career at Genta, where he was vice president, research and technology and had more than 75 issued patents and patent applications.

    While at Genta, Bob became one of the only R&D executives in the biotechnology industry to follow a systemically administered oligonucleotide therapeutic (Genasense™) from the research bench through Phase 1, 2 and 3 clinical trials and NDA review. He worked directly with clinicians and study investigators on trial design, execution and interpretation of results. In addition to his roles at Genta, Bob was co-founder and vice president of research and development at Oasis Biosciences.

    Bob holds a Ph.D. in molecular biology from the University of California, Berkeley, and B.S. degrees in chemistry and biology from the University of Washington.

  • Jack Green

    Chief Financial Officer

    Jack Green joined Dicerna as Chief Financial Officer in April 2016. Prior to Dicerna, he was Chief Financial Officer of Verastem, Inc. (VSTM). Previously, Jack served for over 15 years as Chief Financial Officer of GTC Biotherapeutics, Inc. (GTCB; formerly Genzyme Transgenics Corporation), which was spun out from Genzyme Corporation as a stand-alone public company.

    Jack is a Certified Public Accountant (CPA) with over 30 years of financial management experience, including 20 within the biotechnology industry. He received a Master’s degree in business administration from Boston University Graduate School of Management and a Bachelor’s degree from the College of the Holy Cross majoring in Economics and Accounting.

  • Jennifer Lockridge, Ph.D.

    Senior Vice President, Program Development

    Jennifer Lockridge, Ph.D., is VP of Program Development at Dicerna Pharmaceuticals and has twenty years of experience in the development of oligonucleotide therapeutics. Prior to joining Dicerna, Dr. Lockridge spent nine years consulting with multiple biotech and large pharmaceutical companies to provide direction and support for early development stage oligonucleotide programs as well as pharmacology and pharmacokinetics expertise.

    From 1996 to 2007, she was employed at Sirna Therapeutics, Inc. (formerly Ribozyme Pharmaceuticals, Inc.).  As Director of Project Management at Sirna, she managed and was involved with all aspects of siRNA and ribozyme development programs.  Dr. Lockridge received her Ph.D. in pharmacology at the Oregon Health Sciences University, Portland, Oregon and pursued postdoctoral training at the FDA’s National Center for Toxicological Research, Jefferson, Arkansas.

  • David Miller, Ph.D.

    Senior Vice President, Corporate Operations

    David Miller, Ph.D., has successfully combined leadership roles in both business and research capacities. He has been a member of five early stage biotech companies, each of which has successfully transitioned to a public company. Currently, he is Senior Vice President, Corporate Operations at Dicerna Pharmaceuticals, Cambridge, MA, where he has been the past eight years.

    At Dicerna, he has also occupied the roles of Vice President of Research Operations and of Business Development.  Dr. Miller was Senior Director, Business Development at Synta Pharmaceuticals, where he had partnering responsibility for their oncology portfolio and played a lead role in a pharma partnership, valued at over $1 billion.  Prior to this, he was Director, Business Development at Altus Biologics where his responsibilities included developing their drug delivery business and the partnering of several biological products.  Dr. Miller was a founder and the head of research for EcoScience Corporation, an agricultural biotechnology company. He began his career at Genetics Institute. Dr. Miller is the inventor on six issued United States patent.  He is a board member of EcoPesticides International, a New Mexico company, and on several public boards in his hometown of Winchester, MA.

    Dr. Miller holds a Ph.D. in molecular biology and biochemistry from Harvard University and a B.S. in biochemistry and biophysics from the University of California, Davis.

  • Ralf Rosskamp, M.D.

    Chief Medical Officer

    Ralf Rosskamp, M.D., joined Dicerna as chief medical officer in June 2017. Dr. Rosskamp brings to Dicerna more than 20 years of research and development (R&D) experience spanning the entire drug development cycle, from pre-clinical through product commercialization. He will be responsible for leading the Company’s clinical development, medical affairs and regulatory functions.

    Prior to joining Dicerna, Dr. Rosskamp was chief medical officer at Summit Therapeutics. In this role, Dr. Rosskamp was responsible for directing and overseeing all clinical development and medical activities for Summit’s clinical candidates in development for the rare genetic disease Duchenne muscular dystrophy and the infectious disease caused by Clostridium difficile bacteria. Prior to Summit, Dr. Rosskamp held executive-level positions in clinical research and drug development at NPS Pharmaceuticals (acquired by Shire), Ikaria, Kos Pharmaceuticals (acquired by Abbott Laboratories), Aventis Pharmaceuticals (formerly Hoechst Marrion Roussel), and Hoechst AG.

    Dr. Rosskamp has been responsible for numerous investigational new drug applications, the design and execution of clinical development programs, and new drug applications across multiple therapeutic areas including diabetes, cardiovascular, respiratory and orphan drugs. Approved products for which Dr. Rosskamp was involved include Amaryl®, Lantus®, Apidra®, Simcor® and Natpara® for the treatment of a rare endocrine disease called hypoparathyroidism.

    Dr. Rosskamp is a member of the Board of Directors of Bioblast Pharma in Tel Aviv, Israel. He has authored more than 20 peer-reviewed publications and published more than 50 scientific abstracts. Dr. Rosskamp is a pediatric endocrinologist with more than 15 years of experience in clinical medicine. He received his M.D. from the University of Bonn, Germany.

  • James B. Weissman

    Chief Business Officer

    James B. Weissman joined Dicerna as chief business officer in January 2012. He has more than 25 years’ experience in the life sciences industry, with extensive international management experience in biotech and pharmaceutical general management, product development, licensing, business development, marketing and M&A activities.

    Prior to Dicerna, James was vice president of business development at MannKind Corporation, responsible for leading the company’s activities related to licensing, new products and strategic planning. Prior to MannKind, James held leadership positions in both business development and marketing at Pfizer Pharmaceuticals, Inc. in Tokyo, most recently as senior director of marketing. In that position, he was responsible for the sales, profit and strategic targets for the company’s specialty products, including central nervous system (CNS), endocrinology, ophthalmology and oncology therapeutics and diversified portfolios.

    James holds a Bachelor of Science degree from Bates College.

  • Rebecca Peterson

    Head of Corporate Communications

    Rebecca Peterson is head of corporate communications at Dicerna. She has more than 20 years of investor relations and corporate communications experience in the biotechnology and healthcare industries.

    Most recently, Rebecca was head of partner relations at Sanofi. For the 15 years prior, she directed all corporate communications functions at Alkermes, including investor relations, public relations, product communications, patient advocacy, partner relations management and internal communications. From 1997 to 2000, Rebecca held various communications positions at Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceuticals), where she expanded the investor relations program for this high-profile biopharmaceutical company. Prior to Millennium, she worked in the public affairs office at Brigham and Women’s Hospital.

    Rebecca earned bachelor’s degrees in public health, journalism and communications from the University of Massachusetts at Amherst and master’s degrees in health communications from Tufts University School of Medicine and Emerson College.

  • Bart Wise, Ph.D., J.D.

    In Memoriam, 1964-2018

    Bart Wise joined Dicerna as senior vice president, intellectual property in October 2015. He has practiced for more than 15 years in the life sciences industry, with extensive experience in intellectual property (IP) strategy and patent portfolio management.

    Prior to Dicerna, Bart had his own law practice, where he assisted clients with licensing, agreements, patent matters, and business issues. Bart also held positions in intellectual property at Roche Molecular Systems, Geron, and most recently, as vice president of Intellectual Property at Five Prime Therapeutics. In that position, he was a member of Five Prime’s leadership team and was responsible for all the company’s intellectual property. Bart began his legal career as an associate at the international IP law firm Finnegan, Henderson, where he worked in litigations, interferences, and patent drafting and prosecution.

    Bart holds a B.S. degree in Chemistry from the University of Kansas, a Ph.D. degree in Biology from Carnegie Mellon University, and a J.D. degree from the University of California, Berkeley School of Law. He was also a Howard Hughes Postdoctoral Research Associate at the University of Chicago.